Brokers

Brokers Issue Forecasts for Pharming Group’s FY2026 Earnings (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHARGet Rating) – Equities research analysts at Oppenheimer lifted their FY2026 EPS estimates for Pharming Group in a research report issued to clients and investors on Thursday, May 12th. Oppenheimer analyst H. Singh now expects that the company will earn $0.06 per share for the year, up from their previous estimate of $0.05.

Separately, Zacks Investment Research cut Pharming Group from a “hold” rating to a “sell” rating in a research note on Tuesday, March 29th.

Shares of Pharming Group stock opened at $8.05 on Monday. The company has a quick ratio of 4.75, a current ratio of 5.33 and a debt-to-equity ratio of 0.72. Pharming Group has a 12 month low of $6.71 and a 12 month high of $12.56. The business has a fifty day simple moving average of $8.52 and a 200 day simple moving average of $8.73. Pharming Group (NASDAQ:PHARGet Rating) last released its earnings results on Thursday, March 17th. The company reported $0.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.01. The firm had revenue of $52.77 million for the quarter, compared to the consensus estimate of $57.59 million.

(Ad)

If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

Several institutional investors have recently made changes to their positions in PHAR. Cowen Prime Advisors LLC grew its stake in shares of Pharming Group by 134.9% during the fourth quarter. Cowen Prime Advisors LLC now owns 14,800 shares of the company’s stock worth $132,000 after purchasing an additional 8,500 shares during the period. Jane Street Group LLC grew its stake in Pharming Group by 37.6% in the third quarter. Jane Street Group LLC now owns 17,441 shares of the company’s stock valued at $164,000 after acquiring an additional 4,767 shares during the period. Finally, Morgan Stanley grew its stake in Pharming Group by 5,208.3% in the second quarter. Morgan Stanley now owns 2,548 shares of the company’s stock valued at $29,000 after acquiring an additional 2,500 shares during the period. 0.03% of the stock is owned by institutional investors and hedge funds.

Pharming Group Company Profile (Get Rating)

Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company’s lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Pharming Group right now?

Before you consider Pharming Group, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Pharming Group wasn’t on the list.

While Pharming Group currently has a “N/A” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.